UTHR UNITED THERAPEUTICS Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: UTHR

Price (delayed)

$240.78

Market cap

$11.33B

P/E Ratio

11.44

Dividend/share

N/A

EPS

$21.04

Enterprise value

$10.82B

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
UNITED THERAPEUTICS's net income has increased by 35% YoY and by 9% QoQ
The company's EPS rose by 32% YoY and by 9% QoQ
The quick ratio has dropped by 54% year-on-year and by 3.3% since the previous quarter
The gross margin has declined by 3.6% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unither.com/
Peers: LLY GILD TEVA PFE

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
47.06M
Market cap
$11.33B
Enterprise value
$10.82B
Valuations
Price to earnings (P/E)
11.44
Price to book (P/B)
1.89
Price to sales (P/S)
4.84
EV/EBIT
8.12
EV/EBITDA
7.8
EV/Sales
4.65
Earnings
Revenue
$2.33B
EBIT
$1.33B
EBITDA
$1.39B
Free cash flow
$747.6M
Per share
EPS
$21.04
Free cash flow per share
$15.97
Book value per share
$127.35
Revenue per share
$49.73
TBVPS
$150.7
Balance sheet
Total assets
$7.17B
Total liabilities
$1.18B
Debt
$700M
Equity
$5.98B
Working capital
$2.75B
Liquidity
Debt to equity
0.12
Current ratio
4.41
Quick ratio
4.07
Net debt/EBITDA
-0.37
Margins
EBITDA margin
59.6%
Gross margin
88.9%
Net margin
42.3%
Operating margin
50.9%
Efficiency
Return on assets
14.5%
Return on equity
17.7%
Return on invested capital
22.9%
Return on capital employed
21%
Return on sales
57.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
2.69%
1 week
2.32%
1 month
1.21%
1 year
5.47%
YTD
9.5%
QTD
4.81%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.33B
Gross profit
$2.07B
Operating income
$1.18B
Net income
$984.8M
Gross margin
88.9%
Net margin
42.3%
UNITED THERAPEUTICS's net income has increased by 35% YoY and by 9% QoQ
The operating income has grown by 21% YoY and by 8% from the previous quarter
The company's revenue rose by 20% YoY and by 6% QoQ
The company's gross profit rose by 16% YoY and by 6% QoQ

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
UTHR P/E details
P/E
11.44
P/B
1.89
P/S
4.84
EV/EBIT
8.12
EV/EBITDA
7.8
EV/Sales
4.65
The company's EPS rose by 32% YoY and by 9% QoQ
The stock's P/E is 20% below its 5-year quarterly average of 14.0 and 7% below its last 4 quarters average of 12.0
The equity has increased by 25% year-on-year and by 4.8% since the previous quarter
UTHR's price to book (P/B) is 3.2% lower than its 5-year quarterly average of 1.9 and 3.2% lower than its last 4 quarters average of 1.9
The company's revenue rose by 20% YoY and by 6% QoQ
The stock's P/S is 7% above its 5-year quarterly average of 4.4

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 22% YoY and by 9% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 13% YoY and by 5% QoQ
The company's return on sales rose by 13% YoY and by 4% QoQ
The ROE has grown by 9% YoY and by 3.5% from the previous quarter

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The current ratio has plunged by 55% YoY and by 5% from the previous quarter
The quick ratio has dropped by 54% year-on-year and by 3.3% since the previous quarter
The debt is 88% less than the equity
UNITED THERAPEUTICS's debt to equity has decreased by 29% YoY and by 14% QoQ
The equity has increased by 25% year-on-year and by 4.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.